Chemical and Molecular Tools for Modulating GPCR Function
用于调节 GPCR 功能的化学和分子工具
基本信息
- 批准号:10551701
- 负责人:
- 金额:$ 37.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAnhedoniaAnimal ModelAnxietyAtrophicAutopsyBiological AssayBrain DiseasesCellular AssayChemicalsClinicalDendritic SpinesDevelopmentDiseaseEngineeringFunctional disorderG-Protein-Coupled ReceptorsGoalsHallucinationsHallucinogensImpaired cognitionImpulsivityKetamineKnowledgeLeadMental DepressionMethodsMolecularMotivationNatural ProductsNeurodegenerative DisordersNeuronal PlasticityNeuronsParkinson DiseasePharmaceutical ChemistryPlayPost-Traumatic Stress DisordersPrefrontal CortexPropertyResearchSafetyStructureStructure-Activity RelationshipSubstance Use DisorderSynapsesTherapeuticTherapeutic EffectTractionWorkanalogcerebral atrophydensityhuman imagingin vivoneuropsychiatric disorderrational designscaffoldsmall moleculetool
项目摘要
PROJECT SUMMARY/ABSTRACT
Evidence from human imaging, postmortem analysis, and animal models suggests that atrophy of neurons in
the prefrontal cortex (PFC) plays a key role in the pathophysiology of both neuropsychiatric and
neurodegenerative diseases. Structural changes—including retraction of dendritic arbors, loss of dendritic
spines, and reductions in synapse density—lead to functional deficits that manifest as impaired cognition,
decreased motivation, anhedonia, high anxiety, and increased impulsivity. Thus, therapeutic strategies aiming
to restore PFC structure/function have broad therapeutic potential. Psychoplastogens—small molecules that
promote structural and functional neuroplasticity in the PFC—produce both rapid and long-lasting therapeutic
effects after a single administration. However, many psychoplastogens, including ketamine and serotonergic
psychedelics, induce hallucinations, which greatly limit their therapeutic potential and clinical scalability.
Fortunately, increasing evidence suggests that the hallucinogenic effects of ketamine and psychedelics may
not be necessary for their therapeutic properties, and our group recently introduced the first non-hallucinogenic
psychoplastogens. The advent of non-hallucinogenic psychoplastogens represents an exciting new direction
for the treatment of many brain disorders, but there is an urgent need to further optimize their efficacy and
safety profiles. Our primary goals are to, 1) establish robust synthetic strategies to psychoplastogenic natural
products and chemical scaffolds that are amenable to medicinal chemistry, 2) develop high-throughput cellular
assays for assessing psychoplastogen efficacy and safety, and 3) advance new in vivo assays uniquely suited
to evaluate the long-lasting effects of psychoplastogens. Taken together, these efforts will enable structure-
activity relationship (SAR) studies of key psychoplastogenic scaffolds, filling the gap in our knowledge about
which structural motifs are critical for both psychoplastogenic and hallucinogenic effects. Ultimately, the work
described here will enable the rational design of safer, non-hallucinogenic alternatives to psychedelics for
treating a wide variety of neuropsychiatric and neurodegenerative diseases.
项目概要/摘要
来自人类成像、尸检分析和动物模型的证据表明,神经元萎缩
前额皮质(PFC)在神经精神和精神疾病的病理生理学中起着关键作用
神经退行性疾病。结构变化——包括树突乔木的缩回、树突的丧失
棘和突触密度的减少——导致功能缺陷,表现为认知受损,
动机降低、快感缺乏、高度焦虑和冲动增加。因此,治疗策略旨在
恢复 PFC 结构/功能具有广泛的治疗潜力。精神塑体素——小分子
促进前额皮质的结构和功能神经可塑性——产生快速和持久的治疗效果
单次给药后的效果。然而,许多精神塑性激素,包括氯胺酮和血清素能药物
致幻剂会引起幻觉,这极大地限制了它们的治疗潜力和临床可扩展性。
幸运的是,越来越多的证据表明氯胺酮和致幻剂的致幻作用可能
对于它们的治疗特性来说并不是必需的,我们的小组最近推出了第一个非致幻剂
精神塑性剂。非致幻性精神塑性剂的出现代表了一个令人兴奋的新方向
用于治疗多种脑部疾病,但迫切需要进一步优化其疗效和
安全概况。我们的主要目标是,1)建立强大的心塑性天然合成策略
适合药物化学的产品和化学支架,2)开发高通量细胞
评估精神质体原功效和安全性的测定,以及 3) 推进独特适合的新体内测定
评估精神塑性剂的长期影响。总而言之,这些努力将使结构
关键心理塑性支架的活性关系(SAR)研究,填补了我们在以下方面的知识空白:
哪些结构基序对于心塑性和致幻作用都至关重要。最终,工作
这里描述的将能够合理设计更安全、非致幻剂的迷幻药替代品
治疗多种神经精神疾病和神经退行性疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David E Olson其他文献
Catalytic C—H Amination for the Preparation of Substituted 1,2-Diamines.
用于制备取代 1,2-二胺的催化 CH 胺化。
- DOI:
10.1002/chin.200901180 - 发表时间:
2009 - 期刊:
- 影响因子:0
- 作者:
David E Olson;J. D. Bois - 通讯作者:
J. D. Bois
Electrophilic Amination of Organometallic Reagents: Recent Discoveries and Mechanistic Insights
有机金属试剂的亲电胺化:最新发现和机理见解
- DOI:
10.1002/chin.201213229 - 发表时间:
2011 - 期刊:
- 影响因子:0
- 作者:
David E Olson - 通讯作者:
David E Olson
David E Olson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David E Olson', 18)}}的其他基金
High-throughput Identification of Non-hallucinogenic Psychoplastogens for Treating Addiction
用于治疗成瘾的非致幻性精神塑性物质的高通量鉴定
- 批准号:
10617846 - 财政年份:2022
- 资助金额:
$ 37.56万 - 项目类别:
Design, Synthesis, and Evaluation of Neural Plasticity-Promoting Analogs of Iboga and Ergoline Alkaloids
Iboga 和麦角林生物碱的神经可塑性促进类似物的设计、合成和评估
- 批准号:
10406167 - 财政年份:2018
- 资助金额:
$ 37.56万 - 项目类别:
Administrative supplement: Design, Synthesis, and Evaluation of Neural Plasticity-Promoting Analogs of Iboga and Ergoline Alkaloids
行政补充:伊博加和麦角林生物碱的神经可塑性促进类似物的设计、合成和评估
- 批准号:
10363580 - 财政年份:2018
- 资助金额:
$ 37.56万 - 项目类别:
Design, Synthesis, and Evaluation of Neural Plasticity-Promoting Analogs of Iboga and Ergoline Alkaloids
Iboga 和麦角林生物碱的神经可塑性促进类似物的设计、合成和评估
- 批准号:
10619199 - 财政年份:2018
- 资助金额:
$ 37.56万 - 项目类别:
Design, Synthesis, and Evaluation of Neural Plasticity-Promoting Analogs of Iboga and Ergoline Alkaloids
Iboga 和麦角林生物碱的神经可塑性促进类似物的设计、合成和评估
- 批准号:
10174954 - 财政年份:2018
- 资助金额:
$ 37.56万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 37.56万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 37.56万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 37.56万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 37.56万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 37.56万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 37.56万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 37.56万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 37.56万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 37.56万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 37.56万 - 项目类别:














{{item.name}}会员




